Gastric Acid

Tegoprazan, a novel therapy for GERD, was well-tolerated and showed rapid, dose-dependent acid suppression, according to results of a phase 1 study.

Patients who used proton pump inhibitors were at higher risk for developing cholangitis, according to study results.